Related references
Note: Only part of the references are listed.Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
Fatima Akdim et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Development of Apolipoprotein B Antisense Molecules as a Therapy for Hyperlipidemia
Tiffany Thomas et al.
CURRENT ATHEROSCLEROSIS REPORTS (2010)
Apolipoprotein B synthesis inhibition: results from clinical trials
Maartje E. Visser et al.
CURRENT OPINION IN LIPIDOLOGY (2010)
Mipomersen as a potential adjunctive therapy for hypercholesterolemia
Neeraj Patel et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia
Maartje E. Visser et al.
JOURNAL OF LIPID RESEARCH (2010)
Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
Fatima Akdim et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Safety signal dampens reception for mipomersen antisense
Jim Kling
NATURE BIOTECHNOLOGY (2010)
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100
Rosie Z. Yu et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2 '-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe
Rosie Z. Yu et al.
CLINICAL PHARMACOKINETICS (2009)
Novel Nonstatin Strategies to Lower Low-Density Lipoprotein Cholesterol
Michael H. Davidson
CURRENT ATHEROSCLEROSIS REPORTS (2009)
Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness
Allen J. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Lipoprotein management in patients with cardiometabolic risk - Consensus conference report from the American diabetes association and the American college of cardiology foundation
John D. Brunzell et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Simvastatin with or without ezetimibe in familial hypercholesterolemia
John J. P. Kastelein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
Frederick F. Samaha et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100
Rosie Z. Yu et al.
DRUG METABOLISM AND DISPOSITION (2007)
MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?
John R. Burnett et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
John J. P. Kastelein et al.
CIRCULATION (2006)
Antisense oligonucleotides as therapeutics for hyperlipidaemias
RM Crooke
EXPERT OPINION ON BIOLOGICAL THERAPY (2005)
Familial hypobetalipoproteinemia: genetics and metabolism
G Schonfeld et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2005)
An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
RM Crooke et al.
JOURNAL OF LIPID RESEARCH (2005)
Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: A randomized, double-blind, placebo-controlled trial
AC Goldberg et al.
MAYO CLINIC PROCEEDINGS (2004)
Tissue disposition of 2 '-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys
RZ Yu et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Efficacy and safety of a potent new selective cholesterol absorption inhibitor, Ezetimibe, in patients with primary hypercholesterolemia
CA Dujovne et al.
AMERICAN JOURNAL OF CARDIOLOGY (2002)